



CME FOUNDATION OF INDIA



EVENT REPORT



Diabetes Summit 2024

"Diabetes Summit 2024" was held in 13th & 14th July, 2024 at Park Inn by Radisson, Ayodhya. It was organized by the CME Foundation of India (CMEFI).

The sole objective of the was to bring leading KOLs amongst General Physician and Diabetologist on one platform and discuss their clinical experiences and expertise in the screening, treatment of Diabetes conditions.

The Introductory speech was given by CMEFI.

CMEFI emphasized the main role played by the CME Foundation of India and we all know how important it is to spread the knowledge known only to a select few to the practising doctors at large.

Date : 13th & 14th July, 2024

Venue : Park Inn by Radisson, Ayodhya

Total Participants : 38

Agenda



13th July, 2024



06:00 p.m. to 8:00 p.m.

Topics	Speakers	Timings
Lecture: Tailoring the management of T2DM a patient centric approach Q & A	Speaker: Dr. Santosh Kumar Singh	06:00 p.m. to 07:00 p.m.
Real World: Consideration of HbA1c levels to choose Oral Hypoglycemic Agents (OHAs) and OHA combinations.	Moderator: Dr. Santosh Kumar Singh	07:00 p.m. to 08:00 p.m.

Summary of Conclave

- The CME conducted Diabetes Summit in Park Inn by Radisson, Ayodhya. It was aimed to bring together well-known General Physician and Diabetologist on one platform and discuss their clinical experiences and expertise in the screening and treatment of Diabetes conditions.
- **CMEFI** welcomed the forum and shared a few thoughts on the topics that were on the agenda.
- **Tailoring the management of T2DM a patient centric approach- Dr. Santosh Kumar Singh**

Dr. Santosh Kumar Singh provided a detailed explanation on tailoring the management of Type 2 Diabetes Mellitus (T2DM) using a patient-centric approach. He emphasized the importance of individualizing treatment plans based on each patient's unique medical history, lifestyle, and preferences. Dr. Singh highlighted the need for comprehensive assessments, including HbA1c levels, comorbidities, and patient capabilities, to guide therapy choices.

He discussed various pharmacological options, including oral hypoglycaemic agents and insulin, stressing the importance of selecting medications that align with the patient's specific health profile and treatment goals. Dr. Singh also underscored the role of non-pharmacological interventions, such as diet modifications, physical activity, and patient education, in managing T2DM effectively.

Dr. Singh emphasized the value of regular monitoring and follow-up to adjust treatment plans as needed and to address any emerging complications promptly. He advocated for a collaborative approach, involving healthcare providers, patients, and their families, to enhance adherence to treatment regimens and improve overall outcomes. By focusing on patient-specific needs and fostering a supportive environment, Dr. Singh believes that management of T2DM can be significantly optimized, leading to better health and quality of life for patients.

- **Real World Consideration of HbA1c levels to choose Oral Hypoglycaemic Agents (OHAs) and OHA combinations- Dr. Santosh Kumar Singh**

Dr. Santosh Kumar Singh provided an in-depth explanation on the real-world considerations of HbA1c levels for choosing Oral Hypoglycaemic Agents (OHAs) and OHA combinations. He emphasized the importance of individualized treatment plans, stating that HbA1c levels play a crucial role in determining the most appropriate OHA therapy. Dr. Singh explained that lower HbA1c levels might indicate the effectiveness of monotherapy, while higher levels often necessitate combination therapy to achieve optimal glycemic control. He highlighted the need to consider patient-specific factors such as age, duration of diabetes, comorbid conditions, and risk of hypoglycaemia when selecting OHAs. Dr. Singh discussed various OHAs, including metformin, sulfonylureas, DPP-4 inhibitors, and SGLT2 inhibitors, explaining their mechanisms of action and suitability based on HbA1c targets.

Furthermore, Dr. Singh stressed the importance of ongoing monitoring and periodic adjustment of treatment regimens to ensure sustained glycemic control and to mitigate any adverse effects. He advocated

for a holistic approach that includes lifestyle modifications alongside pharmacotherapy to enhance treatment efficacy and patient adherence. By integrating HbA1c levels into the decision-making process, Dr. Singh believes that personalized OHA strategies can significantly improve outcomes for patients with Type 2 Diabetes Mellitus.

- Different cases were explained to the audience, and the entire case discussion focused on the complications and management of diabetes conditions. The audience actively participated, engaging in a dynamic and interactive session. The delegates thoroughly enjoyed the opportunity to contribute to the discussion and share their insights on various aspects of diabetes complications and their management.
 - Participants were keen to share their experience and knowledge and they also provided their critiques and recommendations on the conclave.
 - **In the end of this CME, the CME Foundation of India extended, its sincere vote of thanks to the attending delegates and acknowledged the academic industry partners for their valuable support and contribution to the success of this conclave.**
1. **Aristo Pharmaceuticals Pvt. Ltd.**
 2. **La Renon Healthcare Pvt. Ltd.**

Snapshots of Success

Welcome to Diabetes Summit 2024



Registration Counter



Lecture on Tailoring the management of T2DM a patient centric approach



Real-World Discussion on Consideration of HbA1c levels to choose Oral Hypoglycemic Agents (OHAs) and OHA combinations.



Delight Attendees Through an Exceptional Conclave Experience



Our Sponsors



Branding Opportunity

